Northwest Biotherapeutics, Inc.
$0.243
Stock Quotes & Analysis
NWBO4.14%
$0.243
Latest AAPL News (Need to figure out how to make this dynamic)
test
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Northwest Biotherapeutics, Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: NWBO
Exchange: OQB
Employees: 25
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
 | 4800 Montgomery Lane, Bethesda, MD, United States |
 | 240 497 9024 |
 | https://www.nwbio.com |